Elicio Therapeutics, Inc.
ELTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 34.9%, free cash flow grew 8.77% and total debt rose 2.12%, each against the same quarter a year earlier.
Follow ELTX
Elicio Therapeutics, Inc. (ELTX) EV/Sales
As of 16 October 2026, Elicio Therapeutics, Inc. (ELTX) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −9.9× (December 2021) to 128× (August 2021); the current reading is higher than 34% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | −0.2× | — |
| FY2020 | 78.2× | 0.00% |
| FY2019 | 78.2× | 0.00% |
| FY2018 | 78.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Jun 2022 | −2.0× | — |
| Mar 2022 | −0.3× | — |
| Dec 2021 | −0.2× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. compare | −9.7× |
| CRBU Caribou Biosciences, Inc. compare | −6.5× |
| ACET Adicet Bio, Inc. compare | −1.8× |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. | 0.6× |
| HOWL Werewolf Therapeutics, Inc. compare | 1.9× |
| HYPD Hyperion DeFi, Inc. compare | 27.9× |
| CLNN Clene Inc. compare | 239× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)